INS and type 2 diabetes mellitus: An electronic health records-based new user, active-comparator, retrospective cohort study of patients with type 2 diabetes and asthma showed that patients on GLP-1RAs for type 2 diabetes had fewer asthma exacerbations compared with other antidiabetic agents (sodium-glucose cotransporter-2 inhibitors [SGLT-2is], dipeptidyl peptidase inhibitors [DPP-4is], sulfonylureas, or basal insulin) [117].